PharmiWeb.com - Global Pharma News & Resources
13-Dec-2018

Biological Industries USA Announces Call for Applications for 2019 Stem Cell Research Awards

Biological Industries USA (BI-USA), the North American division of Biological Industries Beit Haemek Israel, one of the world’s leading suppliers to the life sciences industry, is proud to announce the expansion of the BI-USA Stem Cell Research Awards Program. These new awards build on the success of the 2018 MSC Research Award Program, while branching out to include more cell types, models, and applications.

The 2019 BI-USA Stem Cell Research Awards are designed to encourage cutting-edge scientific research using a variety of cell types that are critical for regenerative medicine applications, including human stem cells (hPSCs and hMSCs), T cells, and endothelial cells. Awards for researchers include BI-USA’s cell culture reagents and services (valued up to $15,000), travel grants for attendance and presentation at scientific conferences, and scientific consultation and support for the duration of the six-month program.

“We are excited and proud to be launching a second round of research awards for the upcoming year,” commented Tanya Potcova, CEO of BI-USA. “In 2018, our MSC Award Program supported research from labs across the country, allowing scientists to explore the use of MSCs for therapeutic applications from a variety of unique perspectives. This inspired us to broaden the awards for 2019 by extending the opportunity to a more diverse range of cell-based research and applications through new grant-based awards. BI-USA hopes to support the development of treatments for acute injuries and chronic diseases that utilize pluripotent and mesenchymal stem cells, as well as T cells and endothelial cells – all key tools for regenerative medicine – by means of this year’s Stem Cell Research Awards.”

BI-USA made the announcement during the 2018 ASCB|EMBO Meeting, in San Diego, California on December 8, 2018.

To apply, researchers must provide basic information about their proposed 6-month study design, including the specific aims of their proposed research study and the overall significance of the study’s findings in downstream pre-clinical or therapeutic applications.

About Biological Industries (BI)

Biological Industries (www.bioind.com) is one of the world’s leading and trusted suppliers to the life sciences industry, with over 35 years’ experience in cell culture media development and GMP manufacturing. BI’s products range from classical cell culture media to supplements and reagents for stem cell research and potential cell therapy applications to serum-free media, and many other products for animal cell culture and molecular biology. BI is committed to a Culture of Excellence through advanced manufacturing and quality-control systems, regulatory expertise, in-depth market knowledge, and extensive technical customer-support, training, and R&D capabilities.

Biological Industries USA (BI-USA) is the US commercialization arm of BI, with facilities in Cromwell, Connecticut. Members of the BI-USA team share a history and expertise of innovation and success in the development of leading-edge technologies in stem cell research, cellular reprogramming, and regenerative medicine.

To receive ongoing BI communications, please join our email list or connect with the company on LinkedInTwitter, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181213005679/en/

Editor Details

Last Updated: 13-Dec-2018